- Report
- February 2024
- 175 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Report
- February 2024
- 204 Pages
Global
From €4557EUR$4,750USD£3,914GBP
- Report
- January 2021
- 600 Pages
United States
From €2686EUR$2,800USD£2,307GBP
- Report
- January 2023
- 150 Pages
United States
From €3789EUR$3,950USD£3,255GBP
- Report
- June 2018
- 99 Pages
Global
From €5708EUR$5,950USD£4,903GBP
- Report
- January 2021
- 900 Pages
United States
From €3166EUR$3,300USD£2,719GBP
- Report
- January 2022
- 121 Pages
Global
From €4557EUR$4,750USD£3,914GBP
- Report
- July 2021
- 50 Pages
China
From €2494EUR$2,600USD£2,143GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£412GBP
- Report
- January 2019
- 35 Pages
Global
From €959EUR$1,000USD£824GBP
- Report
- August 2020
- 113 Pages
Global
From €4317EUR$4,500USD£3,708GBP
Xeloda (capecitabine) is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of oral chemotherapy, meaning it is taken in pill form. Xeloda is used in combination with other drugs to treat NSCLC, and is often used in the later stages of the disease. It works by blocking the growth of cancer cells and preventing them from spreading. Xeloda is also used to treat other types of cancer, such as breast, colorectal, and gastric cancer.
Xeloda is a widely used drug in the treatment of NSCLC, and is often prescribed in combination with other drugs. It is generally well tolerated, with few side effects. Xeloda is available in generic form, as well as under the brand name Xeloda.
The Xeloda market is highly competitive, with many companies offering the drug. Some of the major players in the market include Roche, Pfizer, Novartis, AstraZeneca, and Merck. Other companies offering Xeloda include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more
